Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2021 Mar 18:11:658234.
doi: 10.3389/fonc.2021.658234. eCollection 2021.

Clinical Application of Liquid Biopsy in Non-Hodgkin Lymphoma

Liwei Lv  1 , Yuanbo Liu  1
Affiliations
Review

Clinical Application of Liquid Biopsy in Non-Hodgkin Lymphoma

Liwei Lv et al. Front Oncol. .

Abstract

Non-Hodgkin lymphoma (NHL) is a common type of hematological malignant tumor, composed of multiple subtypes that originate from B lymphocytes, T lymphocytes, and natural killer cells. A diagnosis of NHL depends on the results of a pathology examination, which requires an invasive tissue biopsy. However, due to their invasive nature, tissue biopsies have many limitations in clinical applications, especially in terms of evaluating the therapeutic response and monitoring tumor progression. To overcome these limitations of traditional tissue biopsies, a technique known as "liquid biopsies" (LBs) was proposed. LBs refer to noninvasive examinations that can provide biological tumor data for analysis. Many studies have shown that LBs can be broadly applied to the diagnosis, treatment, prognosis, and monitoring of NHL. This article will briefly review various LB methods that aim to improve NHL management, including the evaluation of cell-free DNA/circulating tumor DNA, microRNA, and tumor-derived exosomes extracted from peripheral blood in NHL.

Keywords: cell-free DNA; circulating tumor DNA; diffuse large B-cell lymphoma; liquid biopsies; microRNA; non-Hodgkin lymphoma; primary central nervous system lymphoma; tumor-derived exosomes.

PubMed Disclaimer

Conflict of interest statement

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Figures

Figure 1
Figure 1
The value of liquid biopsy. ctDNA, circulating tumor DNA.
Figure 2
Figure 2
Summary of clinical application of liquid biopsy in non-Hodgkin’s lymphoma. LBs, liquid biopsies; NHL, non-Hodgkin’s lymphoma; cfDNA, cell-free DNA; ctDNA, circulating tumor DNA; miRNA, microRNA; TDE, tumor-derived exosomes; MRD, minimal residual disease.
See this image and copyright information in PMC

References

    1. Sujobert P, Salles G, Bachy E. Molecular Classification of Diffuse Large B-cell Lymphoma: What Is Clinically Relevant? Hematol Oncol Clin North Am (2016) 30(6):1163–77. 10.1016/j.hoc.2016.07.001 - DOI - PubMed
    1. Ofori K, Bhagat G, Rai AJ. Exosomes and extracellular vesicles as liquid biopsy biomarkers in diffuse large B-cell lymphoma: Current state of the art and unmet clinical needs. Br J Clin Pharmacol (2021) 87(2):284–94. 10.1111/bcp.14611 - DOI - PubMed
    1. Roth P, Martus P, Kiewe P, Möhle R, Klasen H, Rauch M, et al. . Outcome of elderly patients with primary CNS lymphoma in the G-PCNSL-SG-1 trial. Neurology (2012) 79(9):890–6. 10.1212/WNL.0b013e318266fcb2 - DOI - PubMed
    1. Ambady P, Fu R, Netto JP, Kersch C, Firkins J, Doolittle ND, et al. . Patterns of relapse in primary central nervous system lymphoma: inferences regarding the role of the neuro-vascular unit and monoclonal antibodies in treating occult CNS disease. Fluids Barriers CNS (2017) 14(1):16. 10.1186/s12987-017-0064-3 - DOI - PMC - PubMed
    1. Jahnke K, Thiel E, Martus P, Herrlinger U, Weller M, Fischer L, et al. . Relapse of primary central nervous system lymphoma: clinical features, outcome and prognostic factors. J Neurooncol (2006) 80(2):159–65. 10.1007/s11060-006-9165-6 - DOI - PubMed

LinkOut - more resources